Frequently Asked Questions about Mainz Biomed B.V. (MYNZ)

Name: Mainz Biomed B.V. (MYNZ) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Mainz Biomed B.V. (MYNZ) do?

Accepted Answer

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test...

Question 2

Is Mainz Biomed B.V. (MYNZ) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of MYNZ reveals an Altman Z-Score of -50.09 and a Piotroski F-Score of 4/9. These metrics, combined with its 5-year revenue trend ($0.00B most recent), help investors decide if MYNZ fits their risk profile.

Question 3

What is the current P/E ratio for MYNZ?

Accepted Answer

As of the latest trading session, Mainz Biomed B.V. (MYNZ) has a trailing P/E ratio of -0.02.

Question 4

Who is the CEO of Mainz Biomed B.V.?

Accepted Answer

The current Chief Executive Officer of Mainz Biomed B.V. is Guido Baechler.

Question 5

What was MYNZ's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Mainz Biomed B.V. reported annual revenues of $0.00B (2025), $0.00B (2024), $0.00B (2023), $0.00B (2022), $0.00B (2021) respectively.

Question 6

Does MYNZ pay a dividend?

Accepted Answer

Mainz Biomed B.V. does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does MYNZ have?

Accepted Answer

In its latest reporting period, Mainz Biomed B.V. generated $-0.01B in Free Cash Flow against a total debt load of $0.00B.

Question 8

What is the Price-to-Book (P/B) ratio of Mainz Biomed B.V.?

Accepted Answer

The Price-to-Book (P/B) ratio for Mainz Biomed B.V. (MYNZ) is currently 0.08.

Question 9

What is the Price-to-Sales (P/S) ratio of MYNZ?

Accepted Answer

Based on trailing twelve-month data, Mainz Biomed B.V. (MYNZ) trades at a Price-to-Sales (P/S) ratio of 7.00.

Question 10

What is Mainz Biomed B.V.'s Return on Equity (ROE)?

Accepted Answer

Mainz Biomed B.V. (MYNZ) has a Return on Equity (ROE) of -465.82%, representing its profitability relative to shareholder equity.

Period	Revenue	Gross Profit	Op. Income	Net Income	EPS
2025-12	537.1K	389.8K	-16.1M	-16.2M	-2.70
2024-12	894K	574.9K	-18.7M	-21.7M	-22.36
2023-12	895.5K	509.7K	-26.6M	-26.3M	-1.62
2022-12	529.9K	182.2K	-26.4M	-26.5M	-1.87
2021-12	577.3K	177.6K	-9.7M	-11.7M	-1.67

Period	Revenue	Gross Profit	Op. Income	Net Income	EPS
2025-12	537.1K	389.8K	-16.1M	-16.2M	-2.70
2024-12	894K	574.9K	-18.7M	-21.7M	-22.36
2023-12	895.5K	509.7K	-26.6M	-26.3M	-1.62
2022-12	529.9K	182.2K	-26.4M	-26.5M	-1.87
2021-12	577.3K	177.6K	-9.7M	-11.7M	-1.67